{"organizations": [], "uuid": "084e86b19c0e25a972641c1c20c33aa74e51fd4a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180420.html", "section_title": "Archive News &amp; Video for Friday, 20 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-takes-steps-to-advance-develop/brief-fda-takes-steps-to-advance-development-of-opioid-use-disorder-treatment-idUSFWN1RX0OR", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Takes Steps To Advance Development Of Opioid Use Disorder Treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.929, "site_type": "news", "published": "2018-04-20T22:13:00.000+03:00", "replies_count": 0, "uuid": "084e86b19c0e25a972641c1c20c33aa74e51fd4a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-takes-steps-to-advance-develop/brief-fda-takes-steps-to-advance-development-of-opioid-use-disorder-treatment-idUSFWN1RX0OR", "ord_in_thread": 0, "title": "BRIEF-FDA Takes Steps To Advance Development Of Opioid Use Disorder Treatment", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "u.s. fda", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 20 (Reuters) - U.S. FDA:\n* U.S. FDA TAKES NEW STEPS TO ADVANCE THE DEVELOPMENT OF INNOVATIVE PRODUCTS FOR TREATING OPIOID USE DISORDER\n* U.S. FDA - FIRST GUIDANCE EXPLAINS FDA’S THINKING ON ISSUES RELEVANT TO SUSTAINED-RELEASE “DEPOT” BUPRENORPHINE PRODUCTS STUDY\n* FDA - WILL ISSUE ADDITIONAL GUIDANCE ON DEVELOPING NOVEL CLINICAL ENDPOINTS WHICH FORM BASIS OF MEDICATION-ASSISTED TREATMENT PRODUCT APPROVALS Source text : ( bit.ly/2HgARje )\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2HgARje", "https://instagram.com/reuters/"], "published": "2018-04-20T22:13:00.000+03:00", "crawled": "2018-04-21T18:11:09.000+03:00", "highlightTitle": ""}